These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30001928)

  • 41. Advances in serological diagnostics of inflammatory myopathies.
    Benveniste O; Stenzel W; Allenbach Y
    Curr Opin Neurol; 2016 Oct; 29(5):662-73. PubMed ID: 27538058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.
    Muro Y; Nakanishi H; Katsuno M; Kono M; Akiyama M
    Clin Chim Acta; 2017 Sep; 472():1-4. PubMed ID: 28687351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
    Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis.
    Lindgren U; Pullerits R; Lindberg C; Oldfors A
    Ann Neurol; 2022 Aug; 92(2):201-212. PubMed ID: 35596584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies.
    Lee SA; Lee HJ; Suh BC; Shin HY; Kim SW; Yoon BA; Choi YC; Park HJ
    PLoS One; 2023; 18(4):e0284409. PubMed ID: 37058449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inclusion body myositis: update.
    Lahouti AH; Amato AA; Christopher-Stine L
    Curr Opin Rheumatol; 2014 Nov; 26(6):690-6. PubMed ID: 25215417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis.
    van der Meulen MF; Hoogendijk JE; Moons KG; Veldman H; Badrising UA; Wokke JH
    Neuromuscul Disord; 2001 Jul; 11(5):447-51. PubMed ID: 11404115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in the early diagnosis and therapy of inclusion body myositis.
    Lilleker JB
    Curr Opin Rheumatol; 2018 Nov; 30(6):644-649. PubMed ID: 30074510
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Budhram A
    Neurology; 2018 May; 90(21):990. PubMed ID: 29784723
    [No Abstract]   [Full Text] [Related]  

  • 50. Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Liewluck T
    Neurology; 2018 May; 90(21):990. PubMed ID: 29784724
    [No Abstract]   [Full Text] [Related]  

  • 51. Sporadic Inclusion Body Myositis and Other Rimmed Vacuolar Myopathies.
    Weihl CC
    Continuum (Minneap Minn); 2019 Dec; 25(6):1586-1598. PubMed ID: 31794461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.
    Brady S; Squier W; Sewry C; Hanna M; Hilton-Jones D; Holton JL
    BMJ Open; 2014 Apr; 4(4):e004552. PubMed ID: 24776709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis.
    Tasca G; Monforte M; De Fino C; Kley RA; Ricci E; Mirabella M
    Muscle Nerve; 2015 Dec; 52(6):956-62. PubMed ID: 25808807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays.
    Damoiseaux J; Vulsteke JB; Tseng CW; Platteel ACM; Piette Y; Shovman O; Bonroy C; Hamann D; De Langhe E; Musset L; Chen YH; Shoenfeld Y; Allenbach Y; Bossuyt X
    Autoimmun Rev; 2019 Mar; 18(3):293-305. PubMed ID: 30639643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Inclusion body myositis (IBM) -- a review].
    Czaplinski A; Renaud S; Fuhr P
    Praxis (Bern 1994); 2003 Apr; 92(14):649-54. PubMed ID: 12723314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pathogenesis of inclusion body myositis: autoimmune or degenerative disease?].
    Uruha A; Nishino I
    Brain Nerve; 2013 Nov; 65(11):1291-8. PubMed ID: 24200607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-Cytosolic 5'-Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis.
    Rietveld A; Wienke J; Visser E; Vree Egberts W; Schlumberger W; van Engelen B; van Royen-Kerkhof A; Lu H; Wedderburn L; Saris C; Tansley S; Pruijn G;
    Arthritis Rheumatol; 2021 Jul; 73(7):1329-1333. PubMed ID: 33497020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis.
    Prayson RA; Cohen ML
    Hum Pathol; 1997 Aug; 28(8):887-92. PubMed ID: 9269823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atypical presentations of inclusion body myositis: Clinical characteristics and long-term outcomes.
    Alamr M; Pinto MV; Naddaf E
    Muscle Nerve; 2022 Dec; 66(6):686-693. PubMed ID: 36052422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.
    Brady S; Squier W; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1240-6. PubMed ID: 23864699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.